In this cohort study, P85-Ab was a robust and accurate biomarker for suspected NPC in outpatient settings. P85-Ab alone may be suggested for populations with asymptomatic or NPC-nonspecific symptoms, and combining P85-Ab with VCA-IgA and EBNA1-IgA may be suggested for populations with NPC-specific symptoms.
Li et al. (Thu,) studied this question.